Satellos Bioscience Inc. (MSCL)
TSX
Real-time Data
01:30 PM
Day's Range
13.4052 wk Range
6.96Overview - MSCL - Satellos Bioscience Inc.
Key Statistics
Valuation
Enterprise Value
309.00M
P/E (Trailing)
‪2.33‬
P/E (Forward)
‪-7.43‬
PEG Ratio
‪0.22‬
Price / Book
‪2.84‬
EV / EBITDA
‪-6.27‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-41.89%‬
Return on Equity
‪-70.44%‬
Ownership
Shares Outstanding
20.83M
Float
17.96M
Held by Insiders
‪6.48%‬
Held by Institutions
‪50.60%‬
Price stats
Beta
‪1.17‬
50-Day Avg
‪11.86‬
200-Day Avg
‪11.01‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
3 analysts
Average price target
‪CA$ 17.67‬Market Cap - MSCL - Satellos Bioscience Inc.
Peers - MSCL - Satellos Bioscience Inc.
Peer Comparison
Compared with companies in Biotechnology listed on TSX.
- MSCLTSXSatellos Bioscience Inc.292.78MMarket Cap+46.71%52-week change2.34P/E (Trailing)‪0.00%‬Profit Margin
- APMTSXAndean Precious Metals Corp.1.08BMarket Cap+28.04%52-week change6.71P/E (Trailing)‪26.46%‬Profit Margin
- AIMTSXAimia Inc.241.29MMarket Cap-15.69%52-week change7.08P/E (Trailing)‪5.24%‬Profit Margin
- BCTTSXBriaCell Therapeutics Corp.48.37MMarket Cap-87.23%52-week change-0.13P/E (Trailing)‪0.00%‬Profit Margin
- APLITSXAppili Therapeutics Inc.1.98MMarket Cap-33.33%52-week change—P/E (Trailing)‪0.00%‬Profit Margin
Profile Summary - MSCL - Satellos Bioscience Inc.
About
Satellos Bioscience Inc. is a clinical-stage biotechnology company specializing in regenerative medicine for degenerative muscle diseases. Its primary mission is to develop novel therapeutics that restore the body's innate muscle repair and regeneration processes, particularly targeting Duchenne muscular dystrophy…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
